Terms: = Prostate cancer AND TMPRSS2, PRSS10, 7113, ENSG00000184012, O15393
953 results:
1. A cross-sectional study of ERG expression and the relationship with clinicopathological features of prostate cancer in Southwestern Uganda.
Mitala Y; Ssenkumba B; Birungi A; Kiconco R; Mutakooha MM; Atwine R
Diagn Pathol; 2024 May; 19(1):67. PubMed ID: 38730435
[TBL] [Abstract] [Full Text] [Related]
2. Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
Weiss S; Lamy P; Rusan M; Nørgaard M; Ulhøi BP; Knudsen M; Kassentoft CG; Farajzadeh L; Jensen JB; Pedersen JS; Borre M; Sørensen KD
Int J Cancer; 2024 Jul; 155(2):298-313. PubMed ID: 38602058
[TBL] [Abstract] [Full Text] [Related]
3. Race-specific coregulatory and transcriptomic profiles associated with DNA methylation and androgen receptor in prostate cancer.
Ramakrishnan S; Cortes-Gomez E; Athans SR; Attwood KM; Rosario SR; Kim SJ; Mager DE; Isenhart EG; Hu Q; Wang J; Woloszynska A
Genome Med; 2024 Apr; 16(1):52. PubMed ID: 38566104
[TBL] [Abstract] [Full Text] [Related]
4. Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs in extracellular vesicles.
Ruzanov P; Evdokimova V; Pachva MC; Minkovich A; Zhang Z; Langman S; Gassmann H; Thiel U; Orlic-Milacic M; Zaidi SH; Peltekova V; Heisler LE; Sharma M; Cox ME; McKee TD; Zaidi M; Lapouble E; McPherson JD; Delattre O; Radvanyi L; Burdach SE; Stein LD; Sorensen PH
J Clin Invest; 2024 Mar; 134(9):. PubMed ID: 38530366
[TBL] [Abstract] [Full Text] [Related]
5. The antiviral potential of the antiandrogen enzalutamide and the viral-androgen signaling interplay in seasonal coronaviruses.
Ogunjinmi OD; Abdullahi T; Somji RA; Bevan CL; Barclay WS; Temperton N; Brooke GN; Giotis ES
J Med Virol; 2024 Mar; 96(3):e29540. PubMed ID: 38529542
[TBL] [Abstract] [Full Text] [Related]
6. Amplification of different satellite-DNAs in prostate cancer.
Ariffen NA; Ornellas AA; Alves G; Shana'ah AM; Sharma S; Kankel S; Jamali E; Theis B; Liehr T
Pathol Res Pract; 2024 Apr; 256():155269. PubMed ID: 38522124
[TBL] [Abstract] [Full Text] [Related]
7. Effect of nonsteroidal anti-inflammatory drugs (aspirin and naproxen) on inflammation-associated proteomic profiles in mouse plasma and prostate during tmprss2-ERG (fusion)-driven prostate carcinogenesis.
Prasad RR; Mishra N; Kant R; Fox JT; Shoemaker RH; Agarwal C; Raina K; Agarwal R
Mol Carcinog; 2024 Jun; 63(6):1188-1204. PubMed ID: 38506376
[TBL] [Abstract] [Full Text] [Related]
8. TP63-TRIM29 axis regulates enhancer methylation and chromosomal instability in prostate cancer.
Sultanov R; Mulyukina A; Zubkova O; Fedoseeva A; Bogomazova A; Klimina K; Larin A; Zatsepin T; Prikazchikova T; Lukina M; Bogomiakova M; Sharova E; Generozov E; Lagarkova M; Arapidi G
Epigenetics Chromatin; 2024 Mar; 17(1):6. PubMed ID: 38481282
[TBL] [Abstract] [Full Text] [Related]
9. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract] [Full Text] [Related]
10. Genomic and Immunologic Correlates in prostate cancer with High Expression of KLK2.
Paniagua-Herranz L; Moreno I; Nieto-Jiménez C; Garcia-Lorenzo E; Díaz-Tejeiro C; Sanvicente A; Doger B; Pedregal M; Ramón J; Bartolomé J; Manzano A; Gyorffy B; Gutierrez-Uzquiza Á; Pérez Segura P; Calvo E; Moreno V; Ocana A
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396898
[TBL] [Abstract] [Full Text] [Related]
11. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
12. Individualized detection of tmprss2-ERG fusion status in prostate cancer: a rank-based qualitative transcriptome signature.
Li Y; Su H; Liu K; Zhao Z; Wang Y; Chen B; Xia J; Yuan H; Huang DS; Gu Y
World J Surg Oncol; 2024 Feb; 22(1):49. PubMed ID: 38331878
[TBL] [Abstract] [Full Text] [Related]
13. Semi-Supervised, Attention-Based Deep Learning for Predicting tmprss2:ERG Fusion Status in prostate cancer Using Whole Slide Images.
Omar M; Xu Z; Rand SB; Alexanderani MK; Salles DC; Valencia I; Schaeffer EM; Robinson BD; Lotan TL; Loda M; Marchionni L
Mol Cancer Res; 2024 Apr; 22(4):347-359. PubMed ID: 38284821
[TBL] [Abstract] [Full Text] [Related]
14. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract] [Full Text] [Related]
15. cAMP-phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression.
Gulliver C; Busiau T; Byrne A; Findlay JE; Hoffmann R; Baillie GS
Mol Oncol; 2024 Mar; 18(3):707-725. PubMed ID: 38126155
[TBL] [Abstract] [Full Text] [Related]
16. The Value of Combined Detection of Serum PSA, MALAT1 and tmprss2-ETV1 in Evaluating the Progress and Prognosis of prostate cancer.
Zhao G; Pan Z; Wang P
Arch Esp Urol; 2023 Oct; 76(8):555-562. PubMed ID: 37960954
[TBL] [Abstract] [Full Text] [Related]
17. A complex with poly(A)-binding protein and EWS facilitates the transcriptional function of oncogenic ETS transcription factors in prostate cells.
Greulich BM; Rajendran S; Downing NF; Nicholas TR; Hollenhorst PC
J Biol Chem; 2023 Dec; 299(12):105453. PubMed ID: 37956771
[TBL] [Abstract] [Full Text] [Related]
18. Epidemiological profile of COVID-19 in patients with prostate cancer undergoing androgen deprivation therapy at a Brazilian cancer Center.
Travalini IG; Vergamini LB; Silva ILAFE; Caruso P; Orellana FM; Curado MP; Zequi SC
Einstein (Sao Paulo); 2023; 21():eAO0273. PubMed ID: 37878968
[TBL] [Abstract] [Full Text] [Related]
19. Loss of feedback regulation between FAM3B and androgen receptor driving prostate cancer progression.
Ma T; Jin L; Bai S; Liu Z; Wang S; Shen B; Cho Y; Cao S; Sun MJS; Fazli L; Zhang D; Wedderburn C; Zhang DY; Mugon G; Ungerleider N; Baddoo M; Zhang K; Schiavone LH; Burkhardt BR; Fan J; You Z; Flemington EK; Dong X; Dong Y
J Natl Cancer Inst; 2024 Mar; 116(3):421-433. PubMed ID: 37847647
[TBL] [Abstract] [Full Text] [Related]
20. Evaluation of HNF1B, KLK3, ELAC2, tmprss2-ERG, and CTNNB1 polymorphisms associated with prostate cancer in samples of patients from HUPE-UERJ.
Menezes RDS; Dornas MC; Campos CFF; Rodeiro DB; Carrerette FB; Oliveira RV; de Souza BA; Alves de Souza Carvalho G; Brito IAA; Silva DA; Damião R; Porto LC
Prostate; 2024 Feb; 84(2):166-176. PubMed ID: 37839045
[TBL] [Abstract] [Full Text] [Related]
[Next]
